BRPI0408024A - combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase - Google Patents

combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase

Info

Publication number
BRPI0408024A
BRPI0408024A BRPI0408024-6A BRPI0408024A BRPI0408024A BR PI0408024 A BRPI0408024 A BR PI0408024A BR PI0408024 A BRPI0408024 A BR PI0408024A BR PI0408024 A BRPI0408024 A BR PI0408024A
Authority
BR
Brazil
Prior art keywords
aromatase inhibitor
rapamycin derivative
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
BRPI0408024-6A
Other languages
English (en)
Inventor
Matthew L Sheman
James J Gibbons Jr
Mark Berger
Robert T Maguire
Robert Friedman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408024(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0408024A publication Critical patent/BRPI0408024A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES ANTINEOPLáSICAS, COMPREENDENDO UM DERIVADO DE RAPAMICINA E UM INIBIDOR DE AROMATASE". A presente invenção provê o uso de combinação de CCI-779 ou 42-O-(2-hidróxi) etil rapamicina e um inibidor de aromatase e o seu uso para a fabricação de um medicamento para o tratamento de neoplasmas.
BRPI0408024-6A 2003-03-05 2004-03-01 combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase BRPI0408024A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45228903P 2003-03-05 2003-03-05
PCT/US2004/006354 WO2004078133A2 (en) 2003-03-05 2004-03-01 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0408024A true BRPI0408024A (pt) 2006-02-14

Family

ID=32962706

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408024-6A BRPI0408024A (pt) 2003-03-05 2004-03-01 combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase

Country Status (20)

Country Link
US (1) US20040176339A1 (pt)
EP (1) EP1603561A2 (pt)
JP (1) JP2006519862A (pt)
KR (1) KR20050109965A (pt)
CN (1) CN1756549A (pt)
AR (1) AR043403A1 (pt)
AU (1) AU2004218439A1 (pt)
BR (1) BRPI0408024A (pt)
CA (1) CA2516353A1 (pt)
CR (1) CR7942A (pt)
EC (1) ECSP056001A (pt)
MX (1) MXPA05009246A (pt)
NI (1) NI200500148A (pt)
NO (1) NO20054133L (pt)
NZ (1) NZ542738A (pt)
RU (1) RU2355399C2 (pt)
TW (1) TW200529829A (pt)
UA (1) UA83484C2 (pt)
WO (1) WO2004078133A2 (pt)
ZA (1) ZA200508029B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
EP1648454A1 (en) * 2003-07-25 2006-04-26 Wyeth Cci-779 lyophilized formulations
BRPI0418373A (pt) * 2004-01-08 2007-05-22 Wyeth Corp composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
MX2007005153A (es) * 2004-10-28 2007-06-26 Wyeth Corp Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
WO2007057457A2 (en) * 2005-11-21 2007-05-24 Novartis Ag Neuroendocrine tumor treatment using mtor inhibitors
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
EA018824B1 (ru) * 2008-11-11 2013-10-30 Эли Лилли Энд Компани КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРОМ КИНАЗЫ p70 S6 И ИНГИБИТОРОМ mTOR
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
CN102612564B (zh) * 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
JP6091431B2 (ja) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用
US9682066B2 (en) * 2012-12-04 2017-06-20 University Of Cincinnati Methods of treating primary brain tumors by administering letrozole
WO2015014284A1 (zh) * 2013-07-31 2015-02-05 北京盛诺基医药科技有限公司 一种乳腺癌的治疗方法
KR102256576B1 (ko) * 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
EP3209330B1 (en) 2014-10-07 2022-02-23 AI Therapeutics, Inc. An inhalable sirolimus formulation for the treatment of pulmonary hypertension

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
PT1318837E (pt) * 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
CN1309421C (zh) * 2001-04-06 2007-04-11 惠氏公司 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
EA007530B1 (ru) * 2001-06-01 2006-10-27 Уайт Противоопухолевые комбинации
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
RU2355399C2 (ru) 2009-05-20
CR7942A (es) 2006-02-07
NO20054133D0 (no) 2005-09-06
NO20054133L (no) 2005-10-03
EP1603561A2 (en) 2005-12-14
RU2005130767A (ru) 2006-02-10
MXPA05009246A (es) 2005-10-19
WO2004078133A8 (en) 2005-09-01
NZ542738A (en) 2009-02-28
ZA200508029B (en) 2007-04-25
WO2004078133A3 (en) 2004-11-11
WO2004078133A2 (en) 2004-09-16
AU2004218439A1 (en) 2004-09-16
UA83484C2 (uk) 2008-07-25
TW200529829A (en) 2005-09-16
NI200500148A (es) 2006-03-30
JP2006519862A (ja) 2006-08-31
ECSP056001A (es) 2006-01-27
KR20050109965A (ko) 2005-11-22
CN1756549A (zh) 2006-04-05
US20040176339A1 (en) 2004-09-09
AR043403A1 (es) 2005-07-27
CA2516353A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
BRPI0408024A (pt) combinações antineoplásicas, compreendendo um derivado de rapamicina e um inibidor de aromatase
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
CY1119601T1 (el) Προαγωγεις αποπτωσης
LTPA2020503I1 (lt) Rapamicino darinys, skirtas kasos vėžio gydymui
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
BRPI0415779A (pt) tratamento de doenças proliferativas usando um oligÈmero antisenso iap e um agente quimioterápico
PT1385551E (pt) Associações antineoplásicas compreendendo cci-779 (derivado de rapamicina) associado a gemcitabina ou fluorouracilo
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
WO2002040000A3 (en) Use of cci-779 as an antineoplastic agent
BR0211769A (pt) Combinações antineoplásicas
BRPI0410888A (pt) uso de derivados de difenilmetano como inibidores de tirosinase
ATE369372T1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
UY27604A1 (es) Compuestos químicos.
AR047757A1 (es) Aminoacidos n,n-dihalogenados y derivados
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
CL2004000836A1 (es) Combinacion antineoplasica sinergica que comprende una combinacion de interferon alfa y cci-779; uso y producto que los contiene.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
BR0309923B1 (pt) Formulação aquosa de poliuretano, e, uso da mesma
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
BRPI0414114A (pt) uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.